Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT
Share your feedback
Discover
Your question will be sent privately to Cynata Therapeutics. The company may choose to make this question public.
Start the conversation
Ask Cynata Therapeutics a question about this announcement.
Share your feedback
Discover